Glenmark Pharmaceuticals Limited (Glenmark), one of India' research-led, integrated pharmaceutical companies, has implemented the re-organisation of its business into Speciality and Generics. The reorganisation process had begun in Q3 FY 2007-08.
The reorganisation was essential as both Glenmark's Speciality and Generics business has grown rapidly, posing a challenge of managing two diverse businesses that had both attained a critical mass. The reorganisation aims to promote sharper focus on generics and specialty as separate businesses with distinctive needs, skill-sets, objectives and growth imperatives and aligned management teams.
As a result of the reorganisation, Glenmark has transferred its Generics and Active Pharmaceutical Ingredients (API) businesses to its subsidiary - Glenmark Generics Limited (GGL). GGL is guided to generate USD 180 million in net sales in FY 08 and USD 255 million in FY 09.
Terrance Coughlin (erstwhile President - API and US Generics, Glenmark) has been appointed as the CEO of GGL. Terrance has over 20 years of experience in the generic pharmaceutical industry and has been with Glenmark since 2004. Glenn Saldanha will function as the Chairman of Glenmark Generics Limited. Glenn has been responsible for launching and running Glenmark's generic and API businesses.
Pushpinder Bindra comes aboard GGL as Chief Operating Officer. Pushpinder has over 30 years of all-round experience in the Pharmaceutical and API Industry. His last assignment was with Ranbaxy Laboratories Ltd. as president and chief technical officer. Also joining GGL as chief financial officer is Percy Birdy (erstwhile vice president - Finance, Glenmark). Percy has over 16 years of experience in his field. His previous assignment was as the Global Finance Controller for Essel Propack, an India head-quartered MNC with manufacturing operations across 20 countries.
Speaking on this development, Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals Ltd., said, "The business reorganisation marks the beginning of a new era in the life of Glenmark. If Glenmark's recent growth was divided in phases, with the period of 2003-07 being the first phase of growth where the company transformed from an India-centric branded generics player into a global, researched based, integrated pharma company in manufacturing and marketing. Here, begins the second phase, where the company aims to become a global end to end specialty company with capability to research, develop and launch its own differentiated branded products. On the Generics side of its business, GGL aims to be a global integrated generic and API leader."
Going forward, GGL would handle the development, manufacture and distribution of generic formulation and API businesses. The parent company Glenmark Pharmaceuticals Ltd will continue to directly manage the novel R&D, biologics and branded formulation businesses of the Glenmark group including India, Brazil, Rest of Latin America (excluding Argentina), Russia/CIS, Africa and Asia.
The Generics business will inherit Glenmark's Goa plant for formulations, the three API plants in India, sales units in the USA and UK and the Argentina oncology operations. In addition, a group from R&D focused on API and Formulation Development will also move to the generics company.
The branded business will remain in Glenmark Pharmaceuticals and retain all remaining assets, branded sales groups in India and overseas and all remaining R&D operations related to NCEs, Biologics and formulation development for brands.